Search the Newsreel

Eli Lilly shares rise on revenue beat, raised outlook

Eli Lilly's shares rose nearly 7% after the drugmaker reported second-quarter revenues of $22.97 billion, exceeding Wall Street expectations, and raised its full-year 2026 revenue outlook to $85 billion to $87 billion. The strong performance was primarily driven by robust demand and sales increases …

Wise Ally International Holdings Limited Provides Consolidated Earnings Guidance for the Six Months Ended 30 June 2026

Eli Lilly and Company elevates Gaurav Mehta to AVP, CMO & Strategic Capabilities

Eli Lilly and Company has promoted Gaurav Mehta to Associate Vice President, CMO, and Strategic Capabilities. Mehta previously served as Executive Director, Marketing and Strategic Capabilities, and has a strong background in marketing leadership roles across various companies including Noise, Zupee, GirnarSoft, OLX South …

Eli Lilly (LLY) Wins FDA Breakthrough Tag For Olomorasib, Is The Stock Still Cheap?

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Eli Lilly (LLY) stock is back in focus after the FDA granted Breakthrough Therapy designation to its investigational drug olomorasib for KRAS G12C-mutant advanced …

Eli Lilly Ripe for Stock Split After Obesity Drug-Fueled Rally

Eli Lilly's stock has surged over 285% since 2022 due to its successful obesity drugs, pushing its share price above $1,000 and making it the first pharma company to exceed a $1 trillion market cap. Analysts and investors suggest the company is ripe for …

Sam’s Town Hotel & Casino, Shreveport sold to Bally’s Corporation

Bally’s Corporation has announced its acquisition of Sam’s Town Hotel & Casino in Shreveport from Boyd Gaming Corporation. This transaction marks a significant change in ownership for the Shreveport casino. The article also includes several other local news updates from the Shreveport area.

Eli Lilly will offer experimental obesity drug early to some patients. Who qualifies?

Eli Lilly announced it will offer its experimental obesity drug, retatrutide, to a limited number of eligible patients before FDA approval. This injectable drug targets three hormone receptors, unlike its predecessor Zepbound, aiming to enhance fullness and fat breakdown. To qualify, patients must be …

Ally Financial (ALLY) insider files Form 144 to resell 5,000 common shares

Stephanie Richard, an affiliate of Ally Financial (ALLY), has filed a Form 144 to sell 5,000 common shares through Morgan Stanley Smith Barney LLC Executive Financial Services, with an aggregate market value of $221,168.00. The filing also notes prior awards of performance shares and …

O'Reilly Automotive Inc. stock outperforms competitors on strong trading day

O'Reilly Automotive Inc. (ORLY) stock rallied 2.31% to $91.83 on Tuesday, outperforming the broader market. This marked the third consecutive day of gains for the stock. The S&P 500 Index and Dow Jones Industrial Average also saw significant increases on the same trading day.

ALLY Maintains Buy Rating -- Price Target Lowered to $51 by Trui

Truist Securities has maintained a Buy rating for Ally Financial (ALLY) but lowered its price target from $54.00 to $51.00, reflecting a cautious outlook despite continued value perception. GuruFocus indicates that ALLY is currently 10.5% overvalued with a GF Value™ of $40.58, and its …

Lilly Opens Pre-Approval Access to Its Next Obesity Drug

This article first appeared on GuruFocus. Eli Lilly (NYSE:LLY) will give a limited number of patients access to retatrutide, its experimental obesity drug, before U.S. approval, the company said. A spokesperson said it is "medically appropriate to make authentic retatrutide available before FDA approval," …

Is Eli Lilly (LLY) Still the Undisputed Leader in the $150 Billion Obesity Drug Market?

Baron Capital, an investment management company, released its Q2 2026 investor letter for the "Baron Health Care Fund". A copy of the letter is available to download here. The Fund gained 11.99% during the quarter, compared with the 10.48% gain for the Russell 3000 …

Price to earnings forward of Ballymore Resources Limited – ASX:BMR

Amplia Signs Collaboration Agreement With Lilly, Evaluating Narmafotinib Plus Lilly’s Kras G12C Inhibitor, Olomorasib, in Non-small Cell Lung Cancer

HIGHLIGHTS Amplia has executed a Clinical Trial Collaboration & Supply Agreement (CTCSA) with Eli Lilly & Company, to evaluate the Company's investigational FAK inhibitor narmafotinib in combination with Lilly's late‑stage investigational next generation KRAS inhibitor olomorasib The collaboration is underpinned by narmafotinib's growing base …

Willy-Food Investments Ltd Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

Ally Financial (ALLY) After Strong Q2 And Buybacks, Is The Stock Still Undervalued?

Ally Financial (ALLY) reported strong Q2 results with increased net interest income and net income, alongside a reduced share count due to buybacks. Despite a recent cool-down in share price momentum, the stock is considered 18.4% undervalued with a fair value of $54.01, primarily …

Sam’s Town Shreveport casino acquisition completes

Bally's has completed its acquisition of Sam's Town Hotel and Casino in Shreveport, Louisiana, from Boyd Gaming, a move that expands Bally's regional gaming and entertainment portfolio. The acquired venue will soon be rebranded under the Bally's name. Entrepreneur Curtis "50 Cent" Jackson expressed …

Asbury Automotive Group Inc (ABG) Gewinnprognose: Zukünftige EPS & Umsatzwachstumsprognosen

Sally Beauty Holdings (SBH) Beats On Earnings, Is It Fully Priced?

Sally Beauty (SBH) Stock Jumps As Margin Gains Outrun Flat Sales

Sally Beauty Stock Jumps 7.8% After Q3 Earnings Beat, Outlook Narrowed

Laurion Capital exits Rallybio (RLYB) position, reports 0% beneficial ownership

Laurion Capital Management LP and its co-managing members, Benjamin Alexander Smith and Janaka Sheehan Maduraperuma, have filed an amended Schedule 13G for Rallybio (RLYB), reporting 0% beneficial ownership of the company's common stock. This filing indicates that Laurion Capital and its associated individuals no …

Sally Beauty Holdings, Inc. 2026: Revenue $935.49M, EPS $0.55— 10-Q Summary

Sally Beauty Holdings, Inc. reported its 2026 quarterly results, showing revenue of $935.49M and diluted EPS of $0.55. The company's net income increased to $54.08M, an 18.3% rise year-over-year, while revenue growth was modest at 0.2%. The Sally brand saw growth, offset by declines …

ORLY Q2 Deep Dive: Market Share Gains Amid Cautious Industry Outlook

ORLY Q2 Deep Dive: Market Share Gains Amid Cautious Industry Outlook Auto parts and accessories retailer O'Reilly Automotive (NASDAQ:ORLY) beat Wall Street's revenue expectations in Q2 CY2026, with sales up 8.1% year on year to $4.89 billion. The company expects the full year's revenue …

Does Ally’s Strong Q2 Results and Leadership Shift Reshape the Bull Case for Ally Financial (ALLY)?

Ally Financial's recent strong Q2 2026 results, featuring increased net interest income and net income, along with a significant share repurchase program, are examined for their impact on the company's investment narrative. The article also highlights a key leadership change, with Sean Leary appointed …

Smart Money is Buying Eli Lilly & Co. (LLY)

Institutional investors, including prominent quantitative managers and hedge funds, significantly increased their positions in Eli Lilly & Co. (LLY) during the last reported quarter. Notable buyers like AQR Capital Management and Fisher Asset Management led the buying, underscoring strong confidence in Lilly's future growth, …

’50 Cent’ enthusiastic about collaboration with Bally’s at newly acquired Shreveport casino

Bally’s Corporation has completed its acquisition of Sam’s Town Shreveport from Boyd Gaming, a move welcomed by entrepreneur Curtis '50 Cent' Jackson. Jackson, who has significant investments in Shreveport's entertainment district, expressed enthusiasm for future collaboration with Bally's to create new entertainment, dining, and …

Sally Beauty Holdings Looks Ready To Move Higher From Here (NYSE:SBH)

Sally Beauty Holdings (SBH) is rated a Strong Buy, with shares considered undervalued and profit growth anticipated for the current year. Despite a slight revenue miss and lowered full-year sales guidance, the company exceeded expectations on adjusted EPS and net income. The Sally Beauty …

Why Sally Beauty Stock Popped Today

Key Points Sally Beauty's profits are rising as its sales stabilize. New product categories could reignite growth.10 stocks we like better than Sally Beauty › Shares of Sally Beauty Holdings (NYSE: SBH) rose on Monday after the specialty retailer reported progress toward achieving sustainable …

Eli Lilly to offer early access to next-gen obesity drug to some patients

Eli Lilly announced it will offer early access to its experimental obesity drug, retatrutide, to a limited number of patients before its U.S. FDA approval. This expanded access program is for patients aged 18 or older with refractory obesity who meet specific medical criteria, …

Eli Lilly (LLY) Wins FDA Breakthrough Tag For Olomorasib, Backs $70 Million Raise

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Eli Lilly (LLY) stock is back in focus after the FDA granted Breakthrough Therapy designation to its investigational drug olomorasib for KRAS G12C-mutant advanced …

O’Reilly Automotive (ORLY) Raises Guidance—Can Margins Keep Up With Growth?

O'Reilly Automotive (ORLY) reported solid Q2 2026 financial results with an 8% increase in sales to $4.89 billion and a maintained gross margin of 51.4%. Despite analysts lowering price targets, they remain bullish on the stock, citing strong operational performance, an increased outlook for …

1 of Wall Street’s Favorite Stocks with Impressive Fundamentals and 2 That Underwhelm

This article evaluates three stocks that have garnered Wall Street's attention, dissecting their fundamentals to determine their genuine promise. It recommends Construction Partners (ROAD) as a buy due to its outstanding revenue growth and profitable incremental sales. Conversely, it advises caution with WESCO (WCC) …

Eli Lilly's Latest Cancer Win Comes With a Big Caveat

This article first appeared on GuruFocus. Eli Lilly (NYSE:LLY) secured another regulatory boost for olomorasib after the FDA granted breakthrough therapy designation to the experimental drug as a standalone treatment for previously treated, advanced pancreatic cancer carrying the KRAS G12C mutation. The decision could …

Lilly's olomorasib receives U.S. FDA's Breakthrough Therapy designation for the treatment of previously treated KRAS G12C-mutant advanced pancreatic cancer

Eli Lilly and Company announced that the U.S. FDA has granted Breakthrough Therapy designation to olomorasib as a monotherapy for treating advanced pancreatic cancer in adults with a KRAS G12C mutation who have undergone at least one prior systemic therapy. This designation aims to …

Read Between These Lines As Eli Lilly, Hot IPO And More Face Key Test

As stocks like Eli Lilly, Twilio, Hinge Health and more move ahead of earnings report, pay attention to these chart lines. Continue Reading